Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922952 | PMC |
| http://dx.doi.org/10.1002/rth2.12675 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of Nonmedical Switches From Reference Infliximab to Biosimilars on Disease Control Within a Rheumatology Practice.
J Pharm Technol
December 2024
Department of Medicine, Larner College of Medicine, The University of Vermont, Burlington, VT, USA.
Infliximab is an anti-tumor necrosis factor agent used to treat rheumatologic disease. Evidence on the safety of switching to biosimilars and the associated risk factors for flares/loss of disease control within rheumatology is limited. The primary objective is to evaluate nonmedical switches from reference infliximab to biosimilars in rheumatology on risks and level of disease control.
View Article and Find Full Text PDFBudget impact analysis of cenobamate for epilepsy patients with drug-resistant focal onset seizures in the Netherlands.
J Med Econ
December 2025
Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands.
Objective: The objective of this study was to explore the financial consequences of adopting cenobamate as a treatment alternative in epilepsy patients with drug-resistant focal onset seizures (FOS) from a societal perspective in the Netherlands.
Methods: A previous budget impact model with a 5-year time horizon was adapted to the Dutch setting accounting for the eligible population, real-world market shares, treatment effectiveness and resource use in two scenarios: cenobamate with constant market share versus cenobamate with linearly increased market share up to 20%. Clinical inputs included treatment response, seizure reduction and adverse events.
Real-world experience and long-term outcomes of a mandatory non-medical switch of adalimumab originator to biosimilars in inflammatory bowel disease.
World J Gastroenterol
December 2024
Department of Gastroenterology, St. Paul's Hospital, Vancouver V6Z 1Y6, British Columbia, Canada.
Background: Over the last decade, the treatment options for inflammatory bowel disease (IBD) have significantly progressed with the emergence of new medications designed to target various immune pathways and mitigate inflammation. Adalimumab (ADA) is a tumor necrosis factor alpha antagonist and stands as an effective treatment for IBD. In April 2021, the province of British Columbia implemented a mandatory non-medical switch policy of the ADA originator Humira to ADA biosimilars.
View Article and Find Full Text PDFBackground: Use of online crowdfunding to mitigate health-related cost burden is common in the US, but its usage among candidates for metabolic and bariatric surgery (MBS) is unknown. We aimed to identify GoFundMe campaigns fundraising for MBS and characterize sources of financial strain. We also aimed to determine factors associated with successful crowdfunding.
View Article and Find Full Text PDFSwitching from rituximab originator to GP2013 or CT-P10 biosimilars in autoimmune rheumatic diseases: drug retention rate and safety data from a multicentric retrospective cohort.
Ther Adv Musculoskelet Dis
November 2024
Department of Medicine, Surgery and Neurosciences, Rheumatology Unit of Azienda Ospedaliero-Universitaria Senese, University of Siena, Siena, Italy.
Article Synopsis
- The study evaluates the safety and effectiveness of switching from the original rituximab (RTX-O) to its biosimilars (RTX-B) in patients with autoimmune rheumatic diseases (ARDs), with a focus on long-term drug retention and safety.
- It included 181 patients who switched to either GP2013 or CT-P10, finding that the drug retention rates were high over 36 months, particularly for GP2013.
- The transition to CT-P10 showed a higher risk of discontinuation, but overall, the switch to RTX-B was deemed safe with a low incidence of adverse events.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!